Found: 83
Select item for more details and to access through your institution.
Drivers of deep molecular response and long‐term outcomes in patients with core binding factor acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 12, p. E360, doi. 10.1002/ajh.27092
- By:
- Publication type:
- Article
Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. 225, doi. 10.1002/ajh.26781
- By:
- Publication type:
- Article
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. E185, doi. 10.1002/ajh.26504
- By:
- Publication type:
- Article
Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 1, p. E1, doi. 10.1002/ajh.25644
- By:
- Publication type:
- Article
Driver mutation‐specific clinical and genomic correlates differ between primary and secondary myelofibrosis.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. E314, doi. 10.1002/ajh.25625
- By:
- Publication type:
- Article
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 1, p. 87, doi. 10.1002/ajh.25335
- By:
- Publication type:
- Article
Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 3, p. 232, doi. 10.1002/ajh.24627
- By:
- Publication type:
- Article
Autoimmune diseases and myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 5, p. E280, doi. 10.1002/ajh.24333
- By:
- Publication type:
- Article
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 11, p. 1036, doi. 10.1002/ajh.24173
- By:
- Publication type:
- Article
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 9, p. 796, doi. 10.1002/ajh.24087
- By:
- Publication type:
- Article
A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 9, p. E156, doi. 10.1002/ajh.23780
- By:
- Publication type:
- Article
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 8, p. 809, doi. 10.1002/ajh.23749
- By:
- Publication type:
- Article
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 7, p. 566, doi. 10.1002/ajh.23454
- By:
- Publication type:
- Article
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 11, p. 1006, doi. 10.1002/ajh.23303
- By:
- Publication type:
- Article
Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10-year experience at single institution.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 11, p. 904, doi. 10.1002/ajh.21851
- By:
- Publication type:
- Article
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/2040620720986641
- By:
- Publication type:
- Article
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 346, doi. 10.1007/s11899-019-00517-9
- By:
- Publication type:
- Article
There’s Risk, and Then There’s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes.
- Published in:
- Current Hematologic Malignancy Reports, 2013, v. 8, n. 4, p. 351, doi. 10.1007/s11899-013-0172-3
- By:
- Publication type:
- Article
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 400, doi. 10.1016/j.clml.2024.02.005
- By:
- Publication type:
- Article
Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 355, doi. 10.1016/j.clml.2023.01.007
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 3, p. 168, doi. 10.1016/j.clml.2023.01.001
- By:
- Publication type:
- Article
Myelodysplastic Syndromes: A New Decade.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 1, p. 1, doi. 10.1016/j.clml.2021.07.031
- By:
- Publication type:
- Article
MPN-390: Study Design and Objectives for a New Cohort of Patients with Myelofibrosis (MF) Enrolled in the Ongoing Connect® Myeloid Disease Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S366, doi. 10.1016/S2152-2650(21)01840-1
- By:
- Publication type:
- Article
AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S293, doi. 10.1016/S2152-2650(21)01700-6
- By:
- Publication type:
- Article
Poster: MPN-390: Study Design and Objectives for a New Cohort of Patients with Myelofibrosis (MF) Enrolled in the Ongoing Connect® Myeloid Disease Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S235, doi. 10.1016/S2152-2650(21)01481-6
- By:
- Publication type:
- Article
Poster: AML-225: Outcome with Intensive Chemotherapy vs Hypomethylating Agent-Based Induction Strategies in Patients Older Than 70 Years with Newly Diagnosed, Favorable-Risk Acute Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S213, doi. 10.1016/S2152-2650(21)01340-9
- By:
- Publication type:
- Article
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies.
- Published in:
- 2021
- By:
- Publication type:
- letter
Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
- Published in:
- 2020
- By:
- Publication type:
- journal article
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
- Published in:
- 2019
- By:
- Publication type:
- journal article
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.
- Published in:
- 2017
- By:
- Publication type:
- journal article
TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Ruxolitinib for myelofibrosis--an update of its clinical effects.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Outcome of diffuse large B-cell lymphoma in the United States had improved over time but racial disaprities remain: review of SEER data.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Outcome of Diffuse Large B-Cell Lymphoma in the United States Has Improved Over Time but Racial Disparities Remain: Review of SEER Data.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 3, p. 257, doi. 10.1016/j.clml.2011.03.012
- By:
- Publication type:
- Article
A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution.
- Published in:
- Acta Haematologica, 2015, v. 133, n. 2, p. 249, doi. 10.1159/000365877
- By:
- Publication type:
- Article
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article